Baiyunshan announced that recently, the subsidiary Zhongyi Pharmaceutical received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration to treat the new functions of eye disorders, and agreed to carry out clinical trials for dry eye. As of the announcement date, Zhongyi Pharmaceutical has invested about 10.11,1400 yuan in research related to eye patch treatment for dry eye syndrome. In 2025, Zhongyi Pharmaceutical's sales volume for eye disorders was 14.51 million yuan. The drug development cycle is long, there are many steps, and there is uncertainty. The company will disclose progress in a timely manner.

Baiyunshan announced that recently, the subsidiary Zhongyi Pharmaceutical received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration to treat the new functions of eye disorders, and agreed to carry out clinical trials for dry eye. As of the announcement date, Zhongyi Pharmaceutical has invested about 10.11,1400 yuan in research related to eye patch treatment for dry eye syndrome. In 2025, Zhongyi Pharmaceutical's sales volume for eye disorders was 14.51 million yuan. The drug development cycle is long, there are many steps, and there is uncertainty. The company will disclose progress in a timely manner.